stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Net income
AstraZeneca PLC's net income for fiscal 2025 was $12.4B, up 42.7% from $8.7B in fiscal 2024. Over the twelve months to 30 September 2026 it was $13.3B. Over the past ten years it has ranged from −$265.0M (fiscal 2021) to $12.4B (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 4 consecutive fiscal years. AstraZeneca PLC ranks 4th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $12.4B | 42.70% |
| FY2024 | $8.7B | 25.97% |
| FY2023 | $6.9B | 175.85% |
| FY2022 | $2.5B | — |
| FY2021 | −$265.0M | — |
| FY2020 | $3.9B | 152.97% |
| FY2019 | $1.5B | (22.33%) |
| FY2018 | $2.0B | (10.51%) |
| FY2017 | $2.2B | (37.30%) |
| FY2016 | $3.6B | 15.74% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $4.0B | 41.41% |
| Jun 2026 | $2.8B | (28.49%) |
| Mar 2026 | $3.9B | 48.88% |
| Dec 2025 | $2.6B | (18.96%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| AZN AstraZeneca PLC | $13.3B |
| ABBV AbbVie Inc. compare | $10.3B |
| NVS Novartis AG compare | $10.0B |
| AMGN Amgen Inc. compare | $9.4B |
| BMY Bristol Myers Squibb Company compare | $9.2B |
| PFE Pfizer Inc. compare | $4.1B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on AZN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement